查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884057

子宫颈癌疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Cervical Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

子宫颈癌疫苗市场成长驱动因子

由于子宫颈癌发生率上升、HPV预防意识增强以及全球疫苗接种率提高，全球子宫颈癌疫苗市场正经历显着增长。根据最近的一项研究，2024 年该市场规模为 108.6 亿美元，预计到 2025 年将达到 123.6 亿美元。预计到 2032 年将进一步成长至 370.1 亿美元，预测期内复合年增长率 (CAGR) 为 17.0%。北美地区在 2024 年以 34.71% 的市占率领先，这主要归功于其较高的疫苗接种率、完善的医疗保健基础设施以及支持快速获得 HPV 疫苗的监管审批。

子宫颈癌是全球女性第四大常见癌症，主要由高危险型人类乳突病毒 (HPV) 的持续感染引起。感染 HIV 的女性罹患子宫颈癌的风险是未感染 HIV 女性的六倍，凸显了预防策略的必要性。 Cervarix、Gardasil 和 Secolin 等疫苗可提供对 HPV 的免疫力，目前已被广泛接受，作为针对子宫颈癌的低风险、长期预防措施。

市场驱动因素与机会

市场成长的驱动因素是子宫颈癌发生率的上升，尤其是在中低收入国家 (LMIC)，这些国家的公众意识、筛检和预防干预措施有限。根据世界卫生组织 2024 年 3 月的数据，2022 年全球将通报约 66 万例新增子宫颈癌病例，造成约 35 万人死亡。这种成长趋势正在推动对有效疫苗接种计划的需求，尤其是针对青少年的疫苗接种计划。

另一个关键驱动因素是支持广泛接种疫苗的公私部门合作关係。政府、非政府组织和製药公司之间的合作，例如2024年Unitaid-Gavi合作项目，正在帮助改善服务不足地区获得子宫颈癌疫苗的机会。这些努力有助于提高公众意识，支持符合文化背景的疫苗接种活动，并解决医疗保健服务取得的社会经济差异。

此外，研发投资和强大的治疗性疫苗研发管线正在为市场扩张创造机会。目前，全球有20多种治疗性HPV疫苗候选产品正在进行临床开发，凸显了新产品在补充疫苗接种和针对早期或復发性子宫颈癌方面的潜力。

市场限制因素与挑战

儘管市场成长强劲，但仍有一些因素限制着市场发展。疫苗犹豫和错误讯息是主要障碍，尤其是在较保守的社会。疫苗会促使不孕和不良反应的误解促使青少年疫苗接种率低下，并限制了整体市场渗透率。根据 Ecancer Medical Science（2024 年 8 月）报告，儘管疫苗的有效性和安全性已得到证实，但错误讯息仍在持续降低疫苗接种率。

中低收入国家医疗基础设施的匮乏也是一项挑战。维持 HPV 疫苗的冷链物流和建立广泛的疫苗接种中心需要大量资源。此外，HPV DNA 检测和筛检的高昂基础设施成本限制了资源匮乏地区疫苗的可近性，从而影响了市场成长。

市场趋势

子宫颈癌疫苗市场的一个显着趋势是单剂疫苗，它简化了接种程序并提高了患者的依从性。世界卫生组织免疫实务策略咨询专家小组（SAGE，2022 年 4 月）证实，单剂疫苗可有效预防 HPV 感染，有助于提高那些难以坚持接种多剂疫苗地区的疫苗接种覆盖率。

美国、澳洲和英国等已开发国家正在推行性别中立的疫苗接种计划，并将接种范围扩大到男孩，这有助于降低HPV感染率和相关癌症的发生率。此外，国产且价格合理的疫苗的出现，例如印度的CERVAVAC（2023年），提高了疫苗的可及性和可负担性，尤其是在资源匮乏的地区。

市场区隔分析

  • 依疫苗类型：在FDA和WHO的批准、广泛应用以及政府支持计画的推动下，预防性疫苗将在2024年占主导地位。由于Lenti-HPV-07和CAN-2409等新型候选疫苗的临床开发，治疗性疫苗预计将以更高的复合年增长率成长。
  • 按技术：分子疫苗占领先地位，其特点是安全性和有效性，利用病毒样颗粒（VLPs）。 由于载体疫苗能够诱发持久的免疫反应，其市场规模持续成长。
  • 分销管道：医院药房占主导地位，因为患者会前往诊所接种疫苗。政府和机构的供应管道在国家疫苗接种计画中也扮演着重要角色。

区域展望

  • 北美：预计到2024年，市场规模将达到37.7亿美元，其中美国将引领市场成长。高发病率、先进的医疗设施和疫苗接种运动是推动市场成长的主要因素。
  • 欧洲：成熟的医疗体系、集中采购以及旨在提高疫苗接种覆盖率的宣传活动预计将推动市场稳步成长。
  • 亚太地区：该地区是成长最快的地区，这主要得益于政府主导的各项举措，例如印度的 "终结子宫颈癌使命" 以及宣传活动的增加。
  • 拉丁美洲、中东和非洲：儘管公共卫生措施正在扩大疫苗接种覆盖范围，但由于公众意识薄弱和基础设施不足等问题，预计成长速度将较为缓慢。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家和地区子宫颈癌盛行率（2024 年）
  • 主要国家及地区监理概况
  • 主要公司产品线分析
  • 主要产业趋势－併购与合作
  • 主要公司新产品发布

第五章：全球子宫颈癌疫苗市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 按疫苗类型划分
    • 预防性疫苗
    • 治疗性疫苗
  • 市场分析、洞察与预测 - 按技术划分
    • 分子生物学疫苗
    • 载体疫苗
    • 其他
  • 市场分析、洞察与预测 - 按分销管道划分
    • 医院
    • 政府及机构供应
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

章节第六章：北美子宫颈癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲子宫颈癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区子宫颈癌疫苗市场分析、洞察与预测（2019-2032）

  • 按…划分国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲子宫颈癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中东与非洲子宫颈癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

章节11：竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 葛兰素史克公司 (GSK plc.)
    • 默克公司 (Merck & Co., Inc.)
    • 印度血清研究所 (Serum Institute of India Pvt. Ltd.)
    • Theravectys
    • ViciniVax
    • 华生生物技术股份有限公司 (Walvax Biotechnology Co., Ltd.)
    • 厦门新华生技有限公司 (Xiamen Innovax Biotech CO., LTD.)
Product Code: FBI113609

Growth Factors of cervical cancer vaccines Market

The global cervical cancer vaccines market is experiencing significant growth due to rising prevalence of cervical cancer, increasing awareness of HPV prevention, and expanded vaccination coverage worldwide. According to recent insights, the market was valued at USD 10.86 billion in 2024, is projected to reach USD 12.36 billion in 2025, and is expected to grow to USD 37.01 billion by 2032, reflecting a CAGR of 17.0% during the forecast period. North America dominated the market in 2024 with a 34.71% share, driven by high adoption rates, established healthcare infrastructure, and regulatory approvals supporting rapid access to HPV vaccines.

Cervical cancer, the fourth most common cancer in women globally, primarily develops due to persistent infection with high-risk types of human papillomavirus (HPV). Women living with HIV have a six-fold higher risk of developing cervical cancer compared to HIV-negative women, emphasizing the need for preventive strategies. Vaccines such as Cervarix, Gardasil, and Cecolin provide immunity against HPV and are currently the mainstay for prevention, offering targeted, low-risk, and long-term protection against cervical cancer.

Market Drivers and Opportunities

The market growth is fueled by the rising prevalence of cervical cancer, particularly in low- and middle-income countries (LMICs) where awareness, screening, and preventive interventions are limited. According to WHO data in March 2024, around 660,000 new cases of cervical cancer were reported in 2022, leading to approximately 350,000 deaths globally. The increasing incidence has heightened the demand for effective vaccination programs, especially in adolescent populations.

Another significant driver is public-private partnerships supporting widespread vaccination. Collaborations between governments, NGOs, and pharmaceutical companies, such as the 2024 partnership between Unitaid and Gavi, are improving access to cervical cancer vaccines in underserved regions. These initiatives enhance public awareness, support culturally appropriate vaccination campaigns, and address socio-economic disparities in healthcare access.

Moreover, R&D investment and a robust pipeline of therapeutic vaccines are creating opportunities for market expansion. Over 20 therapeutic HPV vaccine candidates are currently in clinical development globally, highlighting the potential for new products to supplement preventive vaccination and target early-stage or recurrent cervical cancer.

Market Restraints and Challenges

Despite strong growth, several factors constrain the market. Vaccine hesitancy and misinformation are major barriers, especially in conservative societies. Myths suggesting vaccines cause infertility or adverse effects reduce adoption rates among adolescents, limiting the overall market penetration. According to Ecancer Medical Science (August 2024), misinformation continues to lower vaccination uptake despite proven efficacy and safety.

Limited healthcare infrastructure in LMICs also poses challenges. Maintaining cold-chain logistics for HPV vaccines and establishing widespread vaccination centers require substantial resources. Additionally, high costs of HPV DNA testing and infrastructure for screening further restrict vaccine access in resource-limited settings, impacting market growth.

Market Trends

A notable trend in the cervical cancer vaccines market is single-dose vaccination, simplifying immunization schedules and enhancing patient compliance. WHO's Strategic Advisory Group of Experts on Immunization (SAGE, April 2022) confirmed that a single dose provides effective protection against HPV, improving vaccination coverage in regions where multi-dose adherence is challenging.

Gender-neutral vaccination programs are emerging in developed countries such as the U.S., Australia, and the U.K., expanding coverage to boys to reduce overall HPV transmission and incidence of related cancers. Additionally, the rise of indigenous and affordable vaccines, like India's CERVAVAC (2023), is improving access and affordability, particularly in low-resource regions.

Segmentation Analysis

  • By Vaccine Type: Preventive vaccines dominate in 2024 due to FDA and WHO approvals, widespread adoption, and government-backed programs. Therapeutic vaccines are projected to grow at a higher CAGR due to clinical development of novel candidates like Lenti-HPV-07 and CAN-2409.
  • By Technology: Molecular-based vaccines lead, leveraging virus-like particles (VLPs) for safety and efficacy. Vector-based vaccines are growing due to their ability to trigger long-lasting immune responses.
  • By Distribution Channel: Hospital pharmacies dominate due to patient visits for vaccination procedures. Government and organizational supply channels also play a significant role in national immunization programs.

Regional Outlook

  • North America: Market size of USD 3.77 billion in 2024, led by the U.S., driven by high prevalence, advanced healthcare facilities, and vaccination campaigns.
  • Europe: Stable growth with mature healthcare systems, centralized procurement, and awareness programs increasing vaccine uptake.
  • Asia Pacific: Fastest-growing region, supported by government initiatives such as India's 'Cervical Cancer Mukt Bharat' mission and rising awareness programs.
  • Latin America & Middle East & Africa: Moderate growth due to limited awareness and infrastructure challenges, though public health initiatives continue to expand vaccination reach.

Competitive Landscape

The market is concentrated with GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd. dominating. GSK leads with Cervarix, Merck with Gardasil, and the Serum Institute expands access through CERVAVAC. Other players such as THERAVECTYS, ViciniVax, and Walvax Biotechnology focus on therapeutic vaccine development and strategic R&D investments to capture market share.

Conclusion

With a market size of USD 10.86 billion in 2024, rising to USD 12.36 billion in 2025, and projected to reach USD 37.01 billion by 2032, the global cervical cancer vaccines market is poised for rapid expansion. Key drivers include increasing HPV prevalence, preventive vaccination programs, single-dose innovations, and gender-neutral strategies. Strategic partnerships, affordable vaccines, and therapeutic vaccine pipelines will shape market growth over the forecast period.

Segmentation By Vaccine Type

  • Preventive Vaccine
  • Therapeutic Vaccine

By Technology

  • Molecular-based
  • Vector-based
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Government & Organization Supply
  • Others

By Region

  • North America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cervical Cancer, by Key Countries/Region, 2024
  • 4.2. Overview of Regol atory Scenario, by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.5. New Product Launches, By Key Players

5. Global Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 5.1.1. Preventive Vaccine
    • 5.1.2. Therapeutic Vaccine
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecol ar-based
    • 5.2.2. Vector-based
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 6.1.1. Preventive Vaccine
    • 6.1.2. Therapeutic Vaccine
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecol ar-based
    • 6.2.2. Vector-based
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 7.1.1. Preventive Vaccine
    • 7.1.2. Therapeutic Vaccine
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecol ar-based
    • 7.2.2. Vector-based
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 8.1.1. Preventive Vaccine
    • 8.1.2. Therapeutic Vaccine
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecol ar-based
    • 8.2.2. Vector-based
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 9.1.1. Preventive Vaccine
    • 9.1.2. Therapeutic Vaccine
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecol ar-based
    • 9.2.2. Vector-based
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 10.1.1. Preventive Vaccine
    • 10.1.2. Therapeutic Vaccine
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecol ar-based
    • 10.2.2. Vector-based
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. THERAVECTYS
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. ViciniVax
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. Xiamen Innovax Biotech CO., LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 2: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 3: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 6: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 7: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 10: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 11: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 14: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 15: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 18: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 19: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 22: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 23: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Cervical Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024 & 2032
  • Figure 3: Global Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024 & 2032
  • Figure 4: Global Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Cervical Cancer Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 7: North America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 8: North America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 9: North America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 10: North America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Cervical Cancer Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Cervical Cancer Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 15: Europe Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 16: Europe Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 17: Europe Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 18: Europe Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 23: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 24: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 25: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 26: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 31: Latin America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 32: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 33: Latin America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 34: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 39: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 40: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 41: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 42: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Cervical Cancer Vaccines Market Share (%), By Company, 2024